Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05208307 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

StatusRecruiting
PhasePhase 2
Started2022-07-21
View on ClinicalTrials.gov ↗
This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. Chemotherapy drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving belantamab mafodotin, pomalidomide, and dexamethasone may kill more cancer cells.

Amendment history 2 changes detected by DataLookout

2026-09-04
Primary completion pushed: 2026-10-21 → 2027-10-21
2026-09-04
Completion pushed: 2027-10-21 → 2028-10-21
Trial Details
NCT Number NCT05208307
Lead Sponsor Emory University
Collaborators: GlaxoSmithKline, National Cancer Institute (NCI)
Conditions Plasma Cell Myeloma
Enrollment 34 participants
Start Date 2022-07-21
Primary Completion 2027-10-21 (estimated)
Study Completion 2028-10-21 (estimated)
Updated on ClinicalTrials.gov 2026-09-03